Release and aggregation of cytochrome c and -synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole

Author： Kakimura J.-i.   Kitamura Y.   Takata K.   Kohno Y.   Nomura Y.   Taniguchi T.  

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.417, Iss.1, 2001-04, pp. : 59-67

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

5-HT 3 Receptor Blocking Properties of the Antiparkinsonian Agent, Talipexole

By Nishio H.   Kohno Y.   Fujii A.   Negishi Y.   Inoue A.   Nakata Y.  

General Pharmacology, Vol. 27, Iss. 5, 1996-07 ,pp. : 779-785

Elsevier

Access to resources Recommend Favorite

Pramipexole: Antiparkinsonian-induced psychotic disorders in an elderly patient: case report

By  

Reactions Weekly, Vol. 1, Iss. 1200, 2008-01 ,pp. : 26-27

Adis International

Access to resources Recommend Favorite

Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys

By Domino E.F.   Ni L.   Zhang H.   Kohno Y.   Sasa M.  

European Journal of Pharmacology, Vol. 325, Iss. 2, 1997-05 ,pp. : 137-144

Elsevier

Access to resources Recommend Favorite

Pramipexole Extended Release: In Parkinson's Disease

By Chwieduk Claudine M.   Curran Monique P.  

CNS Drugs, Vol. 24, Iss. 4, 2010-04 ,pp. : 327-336

Adis International

Access to resources Recommend Favorite

RNAi of cat-2, a Putative Tyrosine Hydroxylase, Increases Alpha Synuclein Aggregation and Associated Effects in Transgenic C. elegans

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 4, 2012-06 ,pp. : 387-394

Bentham Science Publishers

Access to resources Recommend Favorite